Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. DSX
2. GNK
3. INTC
4. SPCX
5. III
6. TTEC
7. DAL
8. AWK
9. ATNI
10. SMG

Go back to Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors
AGIOS PHARM (NASDAQ: AGIO) Delayed: 34.16 +1.08 (3.26%)
Previous Close $33.08    52 Week High $71.49 
Open $33.90    52 Week Low $33.50 
Day High $34.45    P/E N/A 
Day Low $33.50    EPS $-1.18 
Volume 2,241,589